BMJ open · 2026
Is molecular breast imaging suitable for use in UK breast cancer pathways? A qualitative study exploring healthcare professionals' perspectives.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elliott Helen, Allen A Joy, Forester Nerys D, Graziadio Sara, Jones William Stephen, Lendrem Clare, Pearce Mark, Powell Timothy, Bray Alison, Scott Jason
Аннотация
OBJECTIVES: To explore healthcare professionals' perspectives on the potential role of molecular breast imaging (MBI) for breast cancer imaging and to inform future clinical study design and implementation.
DESIGN: Qualitative interview study.
SETTING: UK National Health Service (NHS) breast screening and diagnostic pathways.
PARTICIPANTS: Purposively sampled stakeholders.
METHOD: Semistructured interviews with key professional stakeholders explored potential MBI pathways and routes to adoption, including barriers and facilitators. Data were analysed thematically.
RESULTS: 22 participants were recruited between January 2020 and October 2021. Barriers to MBI adoption were identified at three levels: scan-related, system-level, and cultural within the screening programme. Overcoming these is likely necessary for implementation. A further theme highlighted the potential for MBI to improve screening in selected patient groups, contingent on addressing these barriers. Specifically, adoption would require advances in next-generation MBI systems, particularly reductions in radiation dose and scan time, alongside prospective clinical studies in UK populations to assess diagnostic accuracy.
CONCLUSIONS: Once identified barriers are overcome, participants perceived that MBI could improve screening pathways, particularly for women with dense breast tissue.
DESIGN: Qualitative interview study.
SETTING: UK National Health Service (NHS) breast screening and diagnostic pathways.
PARTICIPANTS: Purposively sampled stakeholders.
METHOD: Semistructured interviews with key professional stakeholders explored potential MBI pathways and routes to adoption, including barriers and facilitators. Data were analysed thematically.
RESULTS: 22 participants were recruited between January 2020 and October 2021. Barriers to MBI adoption were identified at three levels: scan-related, system-level, and cultural within the screening programme. Overcoming these is likely necessary for implementation. A further theme highlighted the potential for MBI to improve screening in selected patient groups, contingent on addressing these barriers. Specifically, adoption would require advances in next-generation MBI systems, particularly reductions in radiation dose and scan time, alongside prospective clinical studies in UK populations to assess diagnostic accuracy.
CONCLUSIONS: Once identified barriers are overcome, participants perceived that MBI could improve screening pathways, particularly for women with dense breast tissue.